Related Experiment Video
Updated: Jan 29, 2026

Immunofluorescence Analysis of Endogenous and Exogenous Centromere-kinetochore Proteins
Published on: March 3, 2016
Endogenous subclinical hyperthyroidism: who, when and why to treat
1a Department of Clinical and Molecular Endocrinology and Oncology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. bebiondi@libero.it.
Abstract:
Subclinical hyperthyroidism is defined as serum thyroid hormone levels within their respective reference ranges in the presence of low-undetectable serum thyrotropin-stimulating hormone levels. Subclinical hyperthyroidism is associated with important cardiovascular risk factors and negative effects on bone metabolism and structure. However, there are conflicting results on cardiovascular mortality and the risk of bone fractures. Treatment and management of subclinical hyperthyroidism is controversial. This article will address the necessity to treat this disorder in relation to the cause of hyperthyroidism, the patient's age, the degree of thyroid-stimulating hormone suppression and the presence of comorbidities.
Related Concept Videos
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Retroviruses
Overview of DNA Repair
Chemically...
Gene Therapy
Induced Pluripotent Stem Cells

